Please enable JavaScript to continue using this application.

Compare $HRGN vs $MGX | Chartloom

Compare

$HRGN vs $MGX

Harvard Apparatus Regenerative Technology Inc · Metagenomi Therapeutics Inc

HRGN

Harvard Apparatus Regenerative Technology Inc

MGX

Metagenomi Therapeutics Inc

Compare $HRGN vs $MGX

Comparing Harvard Apparatus Regenerative Technology Inc and Metagenomi Therapeutics Inc

HRGNHarvard Apparatus Regenerative Technology Inc

MGXMetagenomi Therapeutics Inc

HRGNHarvard Apparatus Regenerative Technology Inc

Market cap

$40M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

44.6%

YTD performance

16.2%

52W performance

-15.8%

FCF yield

-9.0%

MGXMetagenomi Therapeutics Inc

Market cap

$38M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.83x

Rev growth (TTM)

-50.7%

YTD performance

-40.1%

52W performance

-68.7%

FCF yield

-227.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

HRGN

MGX

Detailed metrics comparison

HRGN

Harvard Apparatus Regenerative Technology Inc

MGX

Metagenomi Therapeutics Inc

Market Cap

HRGN$40M

MGX$38M

Enterprise Value

HRGN$41M

MGX$-1M

Price

HRGN$2.30

MGX$1.00

P/E Ratio

HRGNN/A

MGXN/A

P/S Ratio

HRGN41.18x

MGX2.72x

EV/Sales

HRGN41.33x

MGX-0.10x

EV/EBITDA

HRGN0.00x

MGX0.00x

P/B Ratio

HRGN507.11x

MGX0.34x

P/FCF Ratio

HRGNN/A

MGXN/A

EV/FCF

HRGN-11.16x

MGX0.02x

PEG Ratio

HRGNN/A

MGXN/A

Forward P/E (NTM)

HRGNN/A

MGXN/A

Forward P/S (NTM)

HRGNN/A

MGX3.83x

Revenue (TTM)

HRGN$982K

MGX$14M

Revenue Growth (YoY)

HRGN44.6%

MGX-50.7%

Forward Rev Growth

HRGN0.0%

MGX30.0%

Gross Margin (TTM)

HRGN7.5%

MGX0.0%

Operating Margin (TTM)

HRGN0.0%

MGX0.0%

EBITDA Margin (TTM)

HRGN-682.9%

MGX-491.3%

Net Margin (TTM)

HRGN-680.5%

MGX-477.5%

FCF Margin (TTM)

HRGN-370.2%

MGX-620.9%

Net Income (TTM)

HRGN$-7M

MGX$-66M

FCF (TTM)

HRGN$-4M

MGX$-86M

EPS (TTM)

HRGN-$0.38

MGX$0.00

ROE (TTM)

HRGN-78637.0%

MGX-5123.0%

ROA (TTM)

HRGN-30701.0%

MGX-3662.0%

ROIC (TTM)

HRGN-77233.0%

MGX-5123.0%

Cash

HRGN$351K

MGX$39M

Debt

HRGN$500K

MGX$0

Net Cash/Debt

HRGN$-149K

MGX$39M

Current Ratio (TTM)

HRGN0.26x

MGX4.50x

Quick Ratio (TTM)

HRGN0.12x

MGX4.37x

Debt/Equity (TTM)

HRGN0.00x

MGX0.00x

Debt/Assets (TTM)

HRGN0.0%

MGX0.0%

Interest Coverage (TTM)

HRGNN/A

MGXN/A

Net Debt/EBITDA (TTM)

HRGN0.00x

MGX0.00x

Beta

HRGN-0.50

MGX0.68

52W Performance

HRGN-15.8%

MGX-68.7%

YTD Performance

HRGN16.2%

MGX-40.1%

% from 52W High

HRGN-21.2%

MGX-74.7%

% from 52W Low

HRGN145.8%

MGX4.2%

Asset Turnover (TTM)

HRGN0.45x

MGX0.10x

FCF Yield (TTM)

HRGN-9.0%

MGX-227.9%

Earnings Yield (TTM)

HRGN-16.5%

MGX-175.2%

Dividend Yield (TTM)

HRGNN/A

MGXN/A

Rule of 40

HRGN-325.5

MGX-671.6

EV/GP/RG

HRGNN/A

MGXN/A

Ticker research

View HRGN research View MGX research

Metric	HRGN Harvard Apparatus Regenerative Technology Inc	MGX Metagenomi Therapeutics Inc
Market & Valuation
Market Cap	$40M	$38M
Enterprise Value	$41M	$-1M
Price	$2.30	$1.00
P/E Ratio	N/A	N/A
P/S Ratio	41.18x	2.72x
EV/Sales	41.33x	-0.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	507.11x	0.34x
P/FCF Ratio	N/A	N/A
EV/FCF	-11.16x	0.02x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.83x
Revenue & Growth
Revenue (TTM)	$982K	$14M
Revenue Growth (YoY)	44.6%	-50.7%
Forward Rev Growth	0.0%	30.0%
Profitability
Gross Margin (TTM)	7.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-682.9%	-491.3%
Net Margin (TTM)	-680.5%	-477.5%
FCF Margin (TTM)	-370.2%	-620.9%
Net Income (TTM)	$-7M	$-66M
FCF (TTM)	$-4M	$-86M
EPS (TTM)	-$0.38	$0.00
ROE (TTM)	-78637.0%	-5123.0%
ROA (TTM)	-30701.0%	-3662.0%
ROIC (TTM)	-77233.0%	-5123.0%
Financial Health
Cash	$351K	$39M
Debt	$500K	$0
Net Cash/Debt	$-149K	$39M
Current Ratio (TTM)	0.26x	4.50x
Quick Ratio (TTM)	0.12x	4.37x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.50	0.68
52W Performance	-15.8%	-68.7%
YTD Performance	16.2%	-40.1%
% from 52W High	-21.2%	-74.7%
% from 52W Low	145.8%	4.2%
Efficiency & Yields
Asset Turnover (TTM)	0.45x	0.10x
FCF Yield (TTM)	-9.0%	-227.9%
Earnings Yield (TTM)	-16.5%	-175.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-325.5	-671.6
EV/GP/RG	N/A	N/A
Ticker research	View HRGN research	View MGX research

Valuation

P/S Ratio

MGX

2.72x

HRGN

41.18x

EV/FCF

HRGN

-11.16x

MGX

0.02x

Growth & revenue

Revenue Growth TTM

HRGN

44.6%

MGX

-50.7%

Forward Revenue Growth

MGX

30.0%

HRGN

0.0%

Profitability & performance

Gross Margin

HRGN

7.5%

MGX

0.0%

ROE

MGX

-5123.0%

HRGN

-78637.0%

FCF Yield %

HRGN

-9.0%

MGX

-227.9%

52-Week Performance

HRGN

-15.8%

MGX

-68.7%

Detailed metrics comparison

HRGN

Harvard Apparatus Regenerative Technology Inc

MGX

Metagenomi Therapeutics Inc

Market Cap

HRGN$40M

MGX$38M

Enterprise Value

HRGN$41M

MGX$-1M

Price

HRGN$2.30

MGX$1.00

P/E Ratio

HRGNN/A

MGXN/A

P/S Ratio

HRGN41.18x

MGX2.72x

EV/Sales

HRGN41.33x

MGX-0.10x

EV/EBITDA

HRGN0.00x

MGX0.00x

P/B Ratio

HRGN507.11x

MGX0.34x

P/FCF Ratio

HRGNN/A

MGXN/A

EV/FCF

HRGN-11.16x

MGX0.02x

PEG Ratio

HRGNN/A

MGXN/A

Forward P/E (NTM)

HRGNN/A

MGXN/A

Forward P/S (NTM)

HRGNN/A

MGX3.83x

Revenue (TTM)

HRGN$982K

MGX$14M

Revenue Growth (YoY)

HRGN44.6%

MGX-50.7%

Forward Rev Growth

HRGN0.0%

MGX30.0%

Gross Margin (TTM)

HRGN7.5%

MGX0.0%

Operating Margin (TTM)

HRGN0.0%

MGX0.0%

EBITDA Margin (TTM)

HRGN-682.9%

MGX-491.3%

Net Margin (TTM)

HRGN-680.5%

MGX-477.5%

FCF Margin (TTM)

HRGN-370.2%

MGX-620.9%

Net Income (TTM)

HRGN$-7M

MGX$-66M

FCF (TTM)

HRGN$-4M

MGX$-86M

EPS (TTM)

HRGN-$0.38

MGX$0.00

ROE (TTM)

HRGN-78637.0%

MGX-5123.0%

ROA (TTM)

HRGN-30701.0%

MGX-3662.0%

ROIC (TTM)

HRGN-77233.0%

MGX-5123.0%

Cash

HRGN$351K

MGX$39M

Debt

HRGN$500K

MGX$0

Net Cash/Debt

HRGN$-149K

MGX$39M

Current Ratio (TTM)

HRGN0.26x

MGX4.50x

Quick Ratio (TTM)

HRGN0.12x

MGX4.37x

Debt/Equity (TTM)

HRGN0.00x

MGX0.00x

Debt/Assets (TTM)

HRGN0.0%

MGX0.0%

Interest Coverage (TTM)

HRGNN/A

MGXN/A

Net Debt/EBITDA (TTM)

HRGN0.00x

MGX0.00x

Beta

HRGN-0.50

MGX0.68

52W Performance

HRGN-15.8%

MGX-68.7%

YTD Performance

HRGN16.2%

MGX-40.1%

% from 52W High

HRGN-21.2%

MGX-74.7%

% from 52W Low

HRGN145.8%

MGX4.2%

Asset Turnover (TTM)

HRGN0.45x

MGX0.10x

FCF Yield (TTM)

HRGN-9.0%

MGX-227.9%

Earnings Yield (TTM)

HRGN-16.5%

MGX-175.2%

Dividend Yield (TTM)

HRGNN/A

MGXN/A

Rule of 40

HRGN-325.5

MGX-671.6

EV/GP/RG

HRGNN/A

MGXN/A

Ticker research

View HRGN research View MGX research

Metric	HRGN Harvard Apparatus Regenerative Technology Inc	MGX Metagenomi Therapeutics Inc
Market & Valuation
Market Cap	$40M	$38M
Enterprise Value	$41M	$-1M
Price	$2.30	$1.00
P/E Ratio	N/A	N/A
P/S Ratio	41.18x	2.72x
EV/Sales	41.33x	-0.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	507.11x	0.34x
P/FCF Ratio	N/A	N/A
EV/FCF	-11.16x	0.02x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.83x
Revenue & Growth
Revenue (TTM)	$982K	$14M
Revenue Growth (YoY)	44.6%	-50.7%
Forward Rev Growth	0.0%	30.0%
Profitability
Gross Margin (TTM)	7.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-682.9%	-491.3%
Net Margin (TTM)	-680.5%	-477.5%
FCF Margin (TTM)	-370.2%	-620.9%
Net Income (TTM)	$-7M	$-66M
FCF (TTM)	$-4M	$-86M
EPS (TTM)	-$0.38	$0.00
ROE (TTM)	-78637.0%	-5123.0%
ROA (TTM)	-30701.0%	-3662.0%
ROIC (TTM)	-77233.0%	-5123.0%
Financial Health
Cash	$351K	$39M
Debt	$500K	$0
Net Cash/Debt	$-149K	$39M
Current Ratio (TTM)	0.26x	4.50x
Quick Ratio (TTM)	0.12x	4.37x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.50	0.68
52W Performance	-15.8%	-68.7%
YTD Performance	16.2%	-40.1%
% from 52W High	-21.2%	-74.7%
% from 52W Low	145.8%	4.2%
Efficiency & Yields
Asset Turnover (TTM)	0.45x	0.10x
FCF Yield (TTM)	-9.0%	-227.9%
Earnings Yield (TTM)	-16.5%	-175.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-325.5	-671.6
EV/GP/RG	N/A	N/A
Ticker research	View HRGN research	View MGX research